A Sweden-based pharmaceutical company Staybe Therapeutics partnered with OCT Clinical, a leading CRO in Eastern Europe, to run a Phase 2b study in three European countries.
This is a multicenter, randomized Phase 2b study, the primary goal of which is to evaluate the efficacy of the study medicine vs. placebo. The study is double-blinded, which means that neither the patient nor the treating physician knows whether the patient is receiving a high or low dose of STA363 - the medicine under study - or a placebo. All trial participants are followed-up for 12 months.
Download the full text of this case study to learn more about the project.
